SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jan. 27, 2006--Medistem Laboratories, Inc. (OTCBB:MDSM), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, announced today the successful development of a novel method of immune response modification utilizing a genetic reprogramming technology involving RNA interference. The recently published research may enable the development of new therapies to treat immune system disorders such as diabetes, arthritis and others.
